Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
56M
-
Shares change
-
+10.5M
-
Total reported value, excl. options
-
$983M
-
Value change
-
+$174M
-
Put/Call ratio
-
0.73
-
Number of buys
-
80
-
Number of sells
-
-49
-
Price
-
$17.56
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q2 2021
157 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q2 2021.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56M shares
of 108M outstanding shares and own 51.65% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (4.7M shares), VR Adviser, LLC (4.56M shares), Rock Springs Capital Management LP (3.76M shares), Foresite Capital Management IV, LLC (3.4M shares), BlackRock Inc. (3.24M shares), VANGUARD GROUP INC (2.57M shares), RENAISSANCE TECHNOLOGIES LLC (2.43M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2M shares), Cormorant Asset Management, LP (2M shares), and Foresite Capital Management III, LLC (1.95M shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.